Indications for: ADUHELM
Alzheimer's disease in mild cognitive impairment or mild dementia.
Initiate titration based on dosing schedule. Give by IV infusion over 1hr every 4 weeks, at least 21 days apart. Infusions 1 and 2: 1mg/kg. Infusions 3 and 4: 3mg/kg. Infusions 5 and 6: 6mg/kg. Infusion 7 and beyond: 10mg/kg.
Risk of amyloid related imaging abnormalities-edema (ARIA-E), amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H). Perform clinical evaluation if ARIA symptoms occur (esp during titration), including MRI testing if indicated. Obtain MRI (within 1yr) prior to initiation, and prior to 7th and 12th infusions. Patients with any pre-treatment localized superficial siderosis, ≥10 brain microhemorrhages, and/or with a brain hemorrhage >1cm within 1yr of treatment initiation: safety has not been established. Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.
Amyloid beta-directed antibody.
ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, fall; hypersensitivity reactions.
Generic Drug Availability:
Single-dose vial (1.7mL, 3mL)—1